Abbreviated Name

Lung Ref Set A App: Massion (2017)

Lead Investigator

Grogan, Eric — Vanderbilt -Ingram Cancer Center

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Grogan, Eric — Vanderbilt -Ingram Cancer Center
• Srivastava, Sudhir — National Cancer Institute
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

No aims available.

Analytic Method

No analytic method available.

Outcome

The CBSI measurement of CYFRA 21-1 is not observed to have discriminatory ability between lung cancer cases and high-risk controls in the dataset sampled from the EDRN Lung Reference Set A. Pre-specied analyses: -sensitivity at 80% specicity: 0:27 (95% CI 0:18; 0:37) - specicity at 80% sensitivity: 0:25 (95% CI 0:16; 0:4). Both observed values are only somewhat greater than 20% (the expected value assuming no discrimination) and 95% condence intervals do not exclude the null. The corresponding positive and negative diagnostic likelihood ratios and the overall AUC similarly do not suggest much discrimination.

Publications

• No publications available at this time for this protocol.

Biomarkers

• CYFRA 21-1

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Jun 13 2017

Estimated Finish Date

Oct 13 2017

Finish Date

Jan 2 2018

Protocol ID

422

Protocol Type

Reference Set

Fields of Research

• UNKNOWN

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1